These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9694432)

  • 1. Cholinergic strategies for Alzheimer's disease.
    Winkler J; Thal LJ; Gage FH; Fisher LJ
    J Mol Med (Berl); 1998 Jul; 76(8):555-67. PubMed ID: 9694432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies.
    Auld DS; Kornecook TJ; Bastianetto S; Quirion R
    Prog Neurobiol; 2002 Oct; 68(3):209-45. PubMed ID: 12450488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cholinergic system in aging and neuronal degeneration.
    Schliebs R; Arendt T
    Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholine, aging, and Alzheimer's disease.
    Muir JL
    Pharmacol Biochem Behav; 1997 Apr; 56(4):687-96. PubMed ID: 9130295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction.
    Schliebs R; Rossner S; Bigl V
    Prog Brain Res; 1996; 109():253-64. PubMed ID: 9009714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excitotoxic lesions of basal forebrain cholinergic neurons: effects on learning, memory and attention.
    Muir JL; Page KJ; Sirinathsinghji DJ; Robbins TW; Everitt BJ
    Behav Brain Res; 1993 Nov; 57(2):123-31. PubMed ID: 7509608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene and cell therapy for the nucleus basalis of Meynert with NGF in Alzheimer's disease.
    Eriksdotter M; Mitra S
    Handb Clin Neurol; 2021; 179():219-229. PubMed ID: 34225964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfunction of the brain cholinergic system during aging and after lesions of the nucleus basalis of Meynert.
    Pepeu G; Marconcini Pepeu I
    J Neural Transm Suppl; 1994; 44():189-94. PubMed ID: 7897390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease.
    Robbins TW; McAlonan G; Muir JL; Everitt BJ
    Behav Brain Res; 1997 Feb; 83(1-2):15-23. PubMed ID: 9062655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term consequences of N-methyl-D-aspartate excitotoxicity in rat magnocellular nucleus basalis: effects on in vivo labelling of cholinergic neurons.
    Harkany T; Grosche J; Mulder J; Horvath KM; Keijser J; Hortobágyi T; Luiten PG; Härtig W
    Neuroscience; 2001; 108(4):611-27. PubMed ID: 11738498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.
    Schliebs R; Arendt T
    J Neural Transm (Vienna); 2006 Nov; 113(11):1625-44. PubMed ID: 17039298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?
    Hernandez CM; Dineley KT
    Curr Drug Targets; 2012 May; 13(5):613-22. PubMed ID: 22300028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.
    Schliebs R
    Neurochem Res; 2005; 30(6-7):895-908. PubMed ID: 16187224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia.
    Dringenberg HC
    Behav Brain Res; 2000 Nov; 115(2):235-49. PubMed ID: 11000423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions?
    Härtig W; Bauer A; Brauer K; Grosche J; Hortobágyi T; Penke B; Schliebs R; Harkany T
    Rev Neurosci; 2002; 13(2):95-165. PubMed ID: 12160262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease.
    Coulson EJ; May LM; Sykes AM; Hamlin AS
    Neuroscientist; 2009 Aug; 15(4):317-23. PubMed ID: 19458382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?
    Martorana A; Esposito Z; Koch G
    CNS Neurosci Ther; 2010 Aug; 16(4):235-45. PubMed ID: 20560995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
    Hampel H; Mesulam MM; Cuello AC; Farlow MR; Giacobini E; Grossberg GT; Khachaturian AS; Vergallo A; Cavedo E; Snyder PJ; Khachaturian ZS
    Brain; 2018 Jul; 141(7):1917-1933. PubMed ID: 29850777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cells engineered to produce acetylcholine: therapeutic potential for Alzheimer's disease.
    Fisher LJ; Raymon HK; Gage FH
    Ann N Y Acad Sci; 1993 Sep; 695():278-84. PubMed ID: 8239296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.